vs
Side-by-side financial comparison of Claritev Corp (CTEV) and iRhythm Holdings, Inc. (IRTC). Click either name above to swap in a different company.
Claritev Corp is the larger business by last-quarter revenue ($246.6M vs $208.9M, roughly 1.2× iRhythm Holdings, Inc.). iRhythm Holdings, Inc. runs the higher net margin — 2.7% vs -32.7%, a 35.3% gap on every dollar of revenue. On growth, iRhythm Holdings, Inc. posted the faster year-over-year revenue change (27.1% vs 6.2%). Claritev Corp produced more free cash flow last quarter ($36.4M vs $14.5M). Over the past eight quarters, iRhythm Holdings, Inc.'s revenue compounded faster (25.8% CAGR vs 2.5%).
iRhythm Holdings is a digital healthcare company focused on cardiac care, developing and commercializing wearable ambulatory heart monitoring devices paired with AI-powered analytical tools. It primarily serves healthcare providers and patients across the United States, helping to detect undiagnosed arrhythmias such as atrial fibrillation through convenient long-term heart rhythm tracking that delivers actionable clinical insights.
CTEV vs IRTC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $246.6M | $208.9M |
| Net Profit | $-80.6M | $5.6M |
| Gross Margin | — | 70.9% |
| Operating Margin | -3.1% | 1.1% |
| Net Margin | -32.7% | 2.7% |
| Revenue YoY | 6.2% | 27.1% |
| Net Profit YoY | 41.6% | 518.5% |
| EPS (diluted) | $-4.88 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $246.6M | $208.9M | ||
| Q3 25 | $246.0M | $192.9M | ||
| Q2 25 | $241.6M | $186.7M | ||
| Q1 25 | $231.3M | $158.7M | ||
| Q4 24 | $232.1M | $164.3M | ||
| Q3 24 | $230.5M | $147.5M | ||
| Q2 24 | $233.5M | $148.0M | ||
| Q1 24 | $234.5M | $131.9M |
| Q4 25 | $-80.6M | $5.6M | ||
| Q3 25 | $-69.8M | $-5.2M | ||
| Q2 25 | $-62.6M | $-14.2M | ||
| Q1 25 | $-71.3M | $-30.7M | ||
| Q4 24 | $-138.0M | $-1.3M | ||
| Q3 24 | $-391.4M | $-46.2M | ||
| Q2 24 | $-576.7M | $-20.1M | ||
| Q1 24 | $-539.7M | $-45.7M |
| Q4 25 | — | 70.9% | ||
| Q3 25 | — | 71.1% | ||
| Q2 25 | — | 71.2% | ||
| Q1 25 | — | 68.8% | ||
| Q4 24 | — | 70.0% | ||
| Q3 24 | — | 68.8% | ||
| Q2 24 | — | 69.9% | ||
| Q1 24 | — | 66.3% |
| Q4 25 | -3.1% | 1.1% | ||
| Q3 25 | 4.1% | -4.4% | ||
| Q2 25 | 6.9% | -10.0% | ||
| Q1 25 | 4.2% | -20.5% | ||
| Q4 24 | -17.8% | -2.5% | ||
| Q3 24 | -146.7% | -34.1% | ||
| Q2 24 | -224.4% | -15.5% | ||
| Q1 24 | -207.4% | -28.9% |
| Q4 25 | -32.7% | 2.7% | ||
| Q3 25 | -28.4% | -2.7% | ||
| Q2 25 | -25.9% | -7.6% | ||
| Q1 25 | -30.8% | -19.3% | ||
| Q4 24 | -59.4% | -0.8% | ||
| Q3 24 | -169.8% | -31.3% | ||
| Q2 24 | -247.0% | -13.6% | ||
| Q1 24 | -230.1% | -34.6% |
| Q4 25 | $-4.88 | $0.18 | ||
| Q3 25 | $-4.23 | $-0.16 | ||
| Q2 25 | $-3.81 | $-0.44 | ||
| Q1 25 | $-4.38 | $-0.97 | ||
| Q4 24 | $-8.49 | $-0.03 | ||
| Q3 24 | $-24.25 | $-1.48 | ||
| Q2 24 | $-35.78 | $-0.65 | ||
| Q1 24 | $-33.40 | $-1.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.8M | $583.8M |
| Total DebtLower is stronger | $4.6B | — |
| Stockholders' EquityBook value | $-173.9M | $152.7M |
| Total Assets | $4.9B | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.8M | $583.8M | ||
| Q3 25 | $39.2M | $565.2M | ||
| Q2 25 | $56.4M | $545.5M | ||
| Q1 25 | $23.1M | $520.6M | ||
| Q4 24 | $16.8M | $535.6M | ||
| Q3 24 | $86.6M | $522.0M | ||
| Q2 24 | $48.8M | $561.5M | ||
| Q1 24 | $58.7M | $569.1M |
| Q4 25 | $4.6B | — | ||
| Q3 25 | $4.5B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $4.5B | — | ||
| Q1 24 | $4.5B | — |
| Q4 25 | $-173.9M | $152.7M | ||
| Q3 25 | $-101.8M | $121.9M | ||
| Q2 25 | $-39.9M | $103.7M | ||
| Q1 25 | $14.8M | $86.7M | ||
| Q4 24 | $84.0M | $90.9M | ||
| Q3 24 | $207.6M | $71.8M | ||
| Q2 24 | $603.4M | $99.2M | ||
| Q1 24 | $1.2B | $90.3M |
| Q4 25 | $4.9B | $1.0B | ||
| Q3 25 | $5.0B | $995.2M | ||
| Q2 25 | $5.1B | $964.0M | ||
| Q1 25 | $5.1B | $926.1M | ||
| Q4 24 | $5.2B | $931.4M | ||
| Q3 24 | $5.3B | $909.7M | ||
| Q2 24 | $5.7B | $919.2M | ||
| Q1 24 | $6.4B | $909.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 304.87× | — | ||
| Q4 24 | 53.67× | — | ||
| Q3 24 | 21.73× | — | ||
| Q2 24 | 7.48× | — | ||
| Q1 24 | 3.85× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $66.3M | $26.2M |
| Free Cash FlowOCF − Capex | $36.4M | $14.5M |
| FCF MarginFCF / Revenue | 14.8% | 6.9% |
| Capex IntensityCapex / Revenue | 12.1% | 5.6% |
| Cash ConversionOCF / Net Profit | — | 4.70× |
| TTM Free Cash FlowTrailing 4 quarters | $-12.3M | $34.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.3M | $26.2M | ||
| Q3 25 | $19.9M | $34.9M | ||
| Q2 25 | $61.2M | $27.7M | ||
| Q1 25 | $-30.1M | $-7.9M | ||
| Q4 24 | $-33.4M | $19.2M | ||
| Q3 24 | $72.8M | $24.3M | ||
| Q2 24 | $18.5M | $11.8M | ||
| Q1 24 | $49.7M | $-52.0M |
| Q4 25 | $36.4M | $14.5M | ||
| Q3 25 | $-16.3M | $20.1M | ||
| Q2 25 | $36.6M | $17.3M | ||
| Q1 25 | $-68.9M | $-17.3M | ||
| Q4 24 | $-63.8M | $12.4M | ||
| Q3 24 | $41.1M | $15.5M | ||
| Q2 24 | $-7.0M | $3.4M | ||
| Q1 24 | $19.2M | $-61.8M |
| Q4 25 | 14.8% | 6.9% | ||
| Q3 25 | -6.6% | 10.4% | ||
| Q2 25 | 15.2% | 9.3% | ||
| Q1 25 | -29.8% | -10.9% | ||
| Q4 24 | -27.5% | 7.5% | ||
| Q3 24 | 17.8% | 10.5% | ||
| Q2 24 | -3.0% | 2.3% | ||
| Q1 24 | 8.2% | -46.8% |
| Q4 25 | 12.1% | 5.6% | ||
| Q3 25 | 14.7% | 7.7% | ||
| Q2 25 | 10.2% | 5.6% | ||
| Q1 25 | 16.8% | 5.9% | ||
| Q4 24 | 13.1% | 4.2% | ||
| Q3 24 | 13.8% | 6.0% | ||
| Q2 24 | 10.9% | 5.7% | ||
| Q1 24 | 13.0% | 7.4% |
| Q4 25 | — | 4.70× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTEV
Segment breakdown not available.
IRTC
| Commercial Payors | $111.7M | 53% |
| Centers For Medicare And Medicaid | $49.2M | 24% |
| Healthcare Institutions | $34.3M | 16% |
| Non Contracted Third Party Payors | $13.7M | 7% |
